We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Urine Liquid Biopsy Test Detects Molecular Evidence of Prostate Cancer

By LabMedica International staff writers
Posted on 29 Mar 2022

A standalone, non-invasive liquid biopsy urine test can, from a single urine specimen, accurately detect molecular evidence of prostate cancer and, if cancer is detected, classify the severity, or the risk grade, of the malignancy. More...

The miR Sentinel Prostate Cancer Test from miR Scientific, LLC (New York, NY, USA) uses proprietary high-throughput technology based on the interrogation of small noncoding RNAs (sncRNAs) extracted from urinary exosomes. The highly accurate, easy-to-administer miR Sentinel Prostate Cancer Test is powered by the miR Disease Management Platform, the company’s proprietary, non-invasive algorithm-based platform for the effective management of targeted diseases, initially focused on urological cancers. The platform uses precise biologic information interrogation techniques to categorize patients into one of four groups: no cancer, low-risk cancer, intermediate-risk cancer, or high-risk cancer. This gives physicians the ability to clearly determine which patients need treatment and which can be safely and non-invasively monitored, helping avoid harmful and costly overtreatment.

One urine sample is all that’s required for the test to accurately diagnose and classify prostate cancer with 95% sensitivity and specificity, thereby avoiding the standard invasive and inaccurate screening procedures. The test was shown in clinical studies to detect and classify clinically significant prostate cancer with over 90% accuracy. Based on these results, the U.S. Food & Drug Administration has granted the test a Breakthrough Device Designation. When comparing the results of the miR Sentinel Prostate Cancer Test to systematic core needle biopsy in men presenting with initial suspicion of prostate cancer, the latest validation study demonstrated a 93% concordance between the two methods of screening and detection regarding the classification of clinically significant cancer.

"We believe that the accuracy, accessibility, and non-invasive features of our award-winning technology will impact the lives of millions of men and forever positively evolve the standard of care for urological cancers," said Sam Salman, Chairman and CEO of miR Scientific.

Related Links:
miR Scientific, LLC 


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
Electrolyte Analyzer
BKE-B
Gold Member
Neonatal Heel Incision Device
Tenderfoot
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Led by Professor Sherry Chan Kit-wa (middle), the HKUMed research team provides the first large-scale Chinese population evidence to support reviewing Hong Kong’s long-term blood-monitoring requirements for clozapine use. (Photo courtesy of HKUMed)

Study Supports Review of Long-Term Blood-Monitoring Guidelines for Clozapine

Treatment-resistant schizophrenia (TRS) is a severe form of schizophrenia for which clozapine remains the only antipsychotic specifically approved by the U.S. Food and Drug Administration (FDA).... Read more

Immunology

view channel
Image: The findings underscore the importance of aligning allergy testing with clinical history and diagnostic guidelines to reduce inappropriate testing and its consequences (Image Credit: iStock)

Survey Finds Gap Between Food Allergy Testing Awareness and Clinical Practice

Food allergy evaluation can be challenging when laboratory results do not match clinical symptoms. Broad food allergy panels may detect sensitization without confirming an actual allergy, potentially leading... Read more

Industry

view channel
Image

Labcorp Partners With Grupo Fleury to Expand Clinical Trial Operations in Brazil

Multinational clinical trials require laboratory partners that combine global expertise with local operational capabilities. Brazil is an important clinical research destination, supported by its diverse... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.